HQHuma QureshiMDSlidesetViral Hepatitis and Liver DiseaseInternational Viral Hepatitis Elimination Meeting (IVHEM) 2017Real-life experiences - bottlenecks & hurdles- Pakistan- Huma Qureshi, MDView Slideset
SlidesetViral Hepatitis and Liver DiseaseInternational Viral Hepatitis Elimination Meeting (IVHEM) 2017Real-life experiences - bottlenecks & hurdles- Denmark- Jeffrey Lazarus, PhD, MIH, MAView Slideset
SlidesetViral Hepatitis and Liver DiseaseInternational Viral Hepatitis Elimination Meeting (IVHEM) 2017Real-life experiences - bottlenecks & hurdles- Brazil- Maria Cássia Jacintho Mendes Correa, MDView Slideset
KPKKhin Pyone KyiMBBS, DBact, MMedSc, PhD, FRCPSlidesetViral Hepatitis and Liver DiseaseInternational Viral Hepatitis Elimination Meeting (IVHEM) 2017Real-life experiences - bottlenecks & hurdles- Myanmar- Khin Pyone Kyi, MBBS, DBact, MMedSc, PhD, FRCPView Slideset
SlidesetViral Hepatitis and Liver DiseaseInternational Viral Hepatitis Elimination Meeting (IVHEM) 2017How to measure your success; globally and locally- Yvan Hutin, MD, PhDView Slideset
JFJordan FeldMD, MPHSlidesetViral Hepatitis and Liver DiseaseInternational Viral Hepatitis Elimination Meeting (IVHEM) 2017Setting the stage - Key challenges in elimination- Jordan Feld, MD, MPHView Slideset
SlidesetViral Hepatitis and Liver DiseaseInternational Viral Hepatitis Elimination Meeting (IVHEM) 2017Real-life experiences - Egypt- Imam Waked, MDView Slideset
SlidesetViral Hepatitis and Liver DiseaseInternational Viral Hepatitis Elimination Meeting (IVHEM) 2017WHO status report: Global response to the strategic framework- Yvan Hutin, MD, PhDView Slideset
GDPGiovanni Di PerriMD, PhDSlidesetHIVEuropean HIV Clinical Forum 2017One pill a day?: Integration novel delivery systems into routine care- Giovanni Di Perri, MD, PhDView Slideset
SlidesetHIVEuropean HIV Clinical Forum 2017Prospects of immunotherapy for treatment- Michael Lederman, MDView Slideset
SlidesetHIVEuropean HIV Clinical Forum 2017Evolution of bone mineral density and MDRD in HIV-infected patients treated with dolutegravir based regimens: results at 48- weeks- A. D'AvinoView Slideset
MPMiłosz ParczewskiMD, PhDSlidesetHIVEuropean HIV Clinical Forum 2017Clinical case presentation- Miłosz Parczewski, MD, PhDView Slideset
